研究課題/領域番号 |
21K15401
|
研究種目 |
若手研究
|
配分区分 | 基金 |
審査区分 |
小区分49020:人体病理学関連
|
研究機関 | 鹿児島大学 (2022) 広島大学 (2021) |
研究代表者 |
NGUYEN THAO 鹿児島大学, 医歯学域歯学系, 助教 (40733837)
|
研究期間 (年度) |
2021-04-01 – 2024-03-31
|
研究課題ステータス |
交付 (2022年度)
|
配分額 *注記 |
4,680千円 (直接経費: 3,600千円、間接経費: 1,080千円)
2023年度: 1,300千円 (直接経費: 1,000千円、間接経費: 300千円)
2022年度: 1,690千円 (直接経費: 1,300千円、間接経費: 390千円)
2021年度: 1,690千円 (直接経費: 1,300千円、間接経費: 390千円)
|
キーワード | EPS8L3 / YAP / HCC / hepatocellular carcinoma / SH3 domain / Hepatocellularcarcinoma / Liver cancer / Carcinogenesis |
研究開始時の研究の概要 |
Transcriptional regulator Yes-associated protein (YAP) is activated in multiple human cancers and plays critical roles in the tumor initiation, progression, metastasis, and drug resistance. Recently, we demonstrated critical role of EPS8L3 (epidermal growth factor receptor kinase substrate 8-like protein 3) in cholangiocarcinoma (CCA), a deadly form of liver cancer. In this application, we will uncover EPS8L3 as a novel oncogenic factor in CCA that maintains YAP stability and promotes YAP nuclear translocation through physical interaction in vitro and in vivo.
|
研究実績の概要 |
EPS8L3 physically interacted with YAP, which induces the transcriptional activity of YAP through cytoplasmic sequestration and proteasomal degradation. EPS8L3 kinase activity was essential for protecting YAP from ubiquitin-mediated degradation and cytoplasmic retention. Downregulating EPS8L3 expression inhibited the survival of YAP-activated cancer cell lines and mouse xenograft models. EPS8L3 upregulation was associated with high levels of YAP expression and poor prognosis in clinical tumor samples, confirming its important role for YAP activity in human HCC. These results uncover EPS8L3 as a novel factor that regulates YAP stability and that targeting the YAP degradation pathway controlled by EPS8L3 is a potential strategy for suppressing YAP activity in cancer.
|
現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
We completed in vitro and in vivo model and obtained significant results as we expected. Additionally, we extended our research model to other types of cancer. We reported our data in 81st annual meeting of Japanese Cancer Association and 112th annual meeting of the Japanese Society of Pathology and prepared the draft of our manscript.
|
今後の研究の推進方策 |
We will try to complete all necessary experiements and data about the roles of EPS8L3 in hepatocellular carcinoma to have a publication. We are generating the specific peptide to prohibit the interaction between EPS8L3 and YAP, then examine its effects on malignant behaviors of HCC. Additionally, we will collaborate and continue our discovery about the interactions between EPS8L3 and YAP in oral cancer.
|